Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Combination therapy

PROVIDER: PRJNA914990 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22862600.fastq.gz	Fastqsanger.gz
	SRR22862601.fastq.gz	Fastqsanger.gz
	SRR22862602.fastq.gz	Fastqsanger.gz
	SRR22862603.fastq.gz	Fastqsanger.gz
	SRR22862604.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 109

Similar Datasets

Staphylococcus aureus

Project description:Antibiotic combination therapy

| PRJDB10142 | ENA

Nobelitin and Sorafenib Combination Therapy

Project description:Nobelitin and Sorafenib Combination Therapy

| PRJNA1029033 | ENA

Project description:Combination-therapy in CTCL - sequencing data

| PRJNA1117212 | ENA

Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis

Project description:To explore the underlying molecular and cellular mechanisms of increased efficacy of the combination therapy regimen, we employed a mouse model of lupus nephritis, MRL/lpr mice, and treated them with monotherapies of prednisone, mycophenolate mofetil, or tacrolimus, or with their combination. Consistent with previous clinical findings, combination therapy markedly improved renal outcome compared to the monotherapies in mice with lupus nephritis. Transcriptomic analysis of their kidneys revealed distinct molecular pathways that were differentially regulated in combination therapy versus monotherapies. Combination therapy not only provided additive immunosuppressive effects, but also induced gene expression and molecular pathways to confer enhanced renoprotection. Specifically, combination therapy inhibited TLR7 expression in the kidneys of mice with lupus nephritis; combination of tacrolimus and mycophenolate mofetil led to better stabilization of the podocyte actin cytoskeleton through the reciprocal regulation of RhoA and Rac1 activities. Combination therapy strongly suppressed the IL-6/Stat3 pathway. These findings were further validated in renal biopsy samples from patients with lupus nephritis before and after treatments with mycophenolate mofetil, tacrolimus or combination therapy. Thus, our study further supports the earlier clinical finding and further provides insights into the molecular basis for increased efficacy of combination therapy.

2020-06-24 | GSE153021 | GEO

Project description:Small molecule combination therapy for myotonic dystrophy type 1

| PRJNA555349 | ENA

Project description:Resistance to Artemisinin-combination Therapy (ACT) in malaria parasites

| PRJNA1066233 | ENA

Targeting the ADPKD methylome using nanoparticle-mediated combination therapy

Project description:Targeting the ADPKD methylome using nanoparticle-mediated combination therapy

| PRJNA834131 | ENA

GBM response to Smo and PI3K inhibitors

2013-09-01 | GSE49416 | GEO

GBM response to Smo and PI3K inhibitors

Project description:Combination therapy with Smo and PI3K inhibitors results in a synergistic effect in reducing tumor growth in PTEN-deficient Glioblastoma. To identify consequences of combination therapy with an Smo inhibitor and a PI3K inhibitor on a genome-wide scale, we performed Affymetrix microarrays with two different PTEN-deficient GBMs treated with single drugs or combination therapy. A small set of genes was significantly affected by combination therapy in hBT70 and/or hBT112, including several genes implicated in GBM prognosis, or identified as targets of Shh, PI3K or S6 pathways 29-33 . There are two different human GBM tumors (BT70 and BT112). Both are PTEN deficient. Samples were treated with DMSO (Control), LDE225 at 1 uM for 5 days, BKM 120 100 nM for 5 days, or LDE225 1 uM and BKM 120 100 nM for 5 days (Combo). Two biological replicates of each condition were analyzed.

2013-09-01 | E-GEOD-49416 | biostudies-arrayexpress

Homo sapiens

Project description:Adult T-cell leukemia-lymphoma and AZT-IFNa combination therapy

| PRJNA120719 | ENA